GlassScriptPhysician profile
Dean T Chiang
NPI 1760484455
$18,545.02
in general payments reported to CMS, 2019-2025
40 companies · $3,933 in 2025
The $3,933 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $2,575 · 2021: $1,774 · 2022: $2,885 · 2023: $3,398 · 2024: $2,643 · 2025: $3,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,838 · Education: $103 · Consulting Fee: $33.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,837.93 |
| Education | $102.54 |
| Consulting Fee | $33.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,209.73 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $2,418.25 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $1,898.14 | 2020-2025 | Tezspire, Actimmune |
| Genzyme Corporation | $1,628.72 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,354.58 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $866.39 | 2019-2025 | |
| Pfizer INC. | $799.12 | 2019-2025 | |
| Optinose US, INC. | $630.73 | 2019-2025 | |
| Csl Behring | $580.14 | 2019-2025 | Hizentra, Haegarda |
| Blueprint Medicines Corporation | $542.38 | 2023-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $515.69 | 2020-2025 | Takhzyro, Cuvitru |
| Genentech USA, INC. | $447.25 | 2019-2024 | Xolair |
| Abbvie INC. | $411.94 | 2022-2024 | Rinvoq |
| Biocryst US Sales Co., LLC | $325.73 | 2022-2025 | Orladeyo |
| Pharming Healthcare, INC. | $294.35 | 2021-2025 | Ruconest |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $250.00 | 2019 | |
| Kaleo, INC. | $246.40 | 2019-2024 | Auvi-Q |
| Leo Pharma INC. | $234.22 | 2022-2025 | Adbry, Anzupgo |
| Grifols USA, LLC | $197.07 | 2019-2024 | Xembify |
| Galderma Laboratories, L.P. | $185.40 | 2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $175.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.61 | 2020-2022 | |
| Incyte Corporation | $137.14 | 2021-2024 | Opzelura |
| Lilly USA, LLC | $111.89 | 2024-2025 | Ebglyss |
| Shire North American Group INC | $110.59 | 2019 | |
| Ionis Pharmaceuticals, INC. | $88.68 | 2025 | Dawnzera |
| Phadia US INC. | $87.53 | 2022-2025 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $84.31 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $81.26 | 2025 | Neffy |
| Cycle Pharmaceuticals INC | $69.27 | 2025 | Sajazir |
| Merck Sharp & Dohme LLC | $68.13 | 2021-2023 | |
| Octapharma USA, INC. | $63.46 | 2022 | |
| Verona Pharma, INC. | $62.89 | 2025 | Ohtuvayre |
| Organon LLC | $61.59 | 2025 | Vtama |
| Adma Biomanufacturing LLC | $33.45 | 2025 | |
| Horizon Therapeutics Plc | $25.74 | 2020 | |
| Intersect Ent, INC. | $25.23 | 2019 | |
| Alk-Abello, INC | $23.80 | 2020 | |
| Seqirus USA INC | $20.28 | 2025 | Flucelvax, Fluad |
| Viatris Specialty LLC | $19.94 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Chiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.